Aclarion Inc Dossier
Qualitative Analysis
Business overview
Aclarion, Inc. (NASDAQ: ACON) is a commercial-stage healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence (AI) algorithms to optimize clinical treatments. The company's primary focus is addressing the massive $134.5 billion U.S. low back and neck pain market. Its centerpiece technology, Nociscan, is the first evidence-supported, cloud-delivered Software-as-a-Service (SaaS) platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. By analyzing chemical biomarkers associated with degenerative disc disease, Nociscan provides objective biochemical insights to personalize treatment plans and improve surgical decision-making.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A prospective, randomized, multi-center study (Chronic Low bAck pain Randomized Independent Trial studY) evaluating Nociscan in up to 300 patients undergoing surgical treatment (Fusion / TDR) for discogenic low back pain to demonstrate its ability to improve surgical outcomes.
Expected impact: Generate high-quality clinical evidence to support commercial expansion, provider adoption, and U.S. reimbursement pathways.
Advancing reimbursement coverage from regional insurance providers in the United States to expand patient access and support commercial adoption of the Nociscan platform.
Expected impact: Replicate successful UK reimbursement wins (where payer approval was secured from three of the top four private insurers) to drive scalable scan volume growth in the U.S.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
PRIA Healthcare will provide expertise in payer engagement, prior authorization support, and appeals management to streamline the reimbursement process for physicians and health systems, removing access barriers for Nociscan in the U.S.
Terms: Terms not publicly disclosed.
Brings Nociscan to the Los Angeles-based clinic to conduct a study comparing Nociscan's chemical biomarker data with bone metabolic information from SPECT-CT imaging, generating critical real-world evidence to support payer and provider adoption.
Terms: Terms not publicly disclosed.
A commercial agreement to use the Nociscan platform in a clinical trial at NewYork-Presbyterian/Weill Cornell Medical Center to assess the long-term effects of lumbar microdiscectomy surgery with and without bone marrow aspirate concentrate injections.
Terms: Terms not publicly disclosed.